clinical trial · NCT06079372
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Alexion Pharmaceuticals, Inc.·phase3·active not recruiting·n = 43
HypophosphatasiaALXN1850asfotase alfa
brief summary
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
started
Apr 2, 2024
primary completion
Jul 23, 2025
completion
Feb 29, 2028
last updated
Mar 12, 2026
official title
A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol